# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday.
ESSA Pharma shares fell 22.6% at $6.80 yesterday. Explore masofaniten's promising Phase 1/2 results in prostate cancer trea...
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earning...
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients...
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Tuesday. Here are some big st...
Oppenheimer analyst Mark Breidenbach reiterates ESSA Pharma (NASDAQ:EPIX) with a Outperform and maintains $17 price target.
ESSA Pharma (NASDAQ:EPIX) reported quarterly losses of $(0.12) per share. This is a 14.29 percent increase over losses of $(0.1...